Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity
Benjamin Diamond, Even H Rustad, Kylee Maclachlan, Katie Thoren, Caleb Ho, Mikhail Roshal, Gary A. Ulaner, Ola Landgren
Topics & Concepts
Minimal residual diseaseMultiple myelomaMedicineOncologyClinical trialMalignancyInternal medicineBone marrowMedical physicsMultiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsPeptidase Inhibition and Analysis